Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Screening Inhaled Allergen Challenge for Der f
NCT03049111Phase 1Terminated
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jan 2018
- Primary completion
- Oct 2019
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial, sponsored by University of North Carolina at Chapel Hill. Primary endpoint: Number of Participants With Decline in FEV1 >= 10% From Pre-challenge. Started Jan 2018; status: terminated.
Beyond the preview
Go deeper on NCT03049111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03049111.